Back to Browse Journals » Cancer Management and Research » Volume 4

Importance of antiresorptive therapies for patients with bone metastases from solid tumors

Authors Talreja DB

Received 18 May 2012

Accepted for publication 7 July 2012

Published 11 September 2012 Volume 2012:4 Pages 287—297


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 7

Draupadi B Talreja

Department of Medicine, David Geffen School of Medicine at UCLA and Northridge Hospital Medical Center, Northridge, CA, USA

Abstract: Patients with bone metastases are at risk of skeletal-related events such as pathologic fractures, spinal cord compression, the need for orthopedic surgery to bone, and palliative radiotherapy for severe bone pain. Antiresorptive therapies have demonstrated efficacy for reducing the risk of skeletal-related events and ameliorating bone pain. Despite the well documented clinical benefits of antiresorptive therapies, patient benefits can be limited or compromised by nonadherence with scheduled therapy. Potential reasons for poor compliance include lack of understanding of how antiresorptive therapies work, neglecting the importance of bone health in maintaining quality of life, and being unaware of the potentially debilitating effects of skeletal-related events caused by bone metastases. Indeed, patients may stop therapy after bone pain subsides or discontinue due to generally mild and usually manageable adverse events, leaving them at an increased risk of developing skeletal-related events. In addition, the cost of antiresorptive therapy can be a concern for many patients with cancer. Medical care for patients with cancer requires a coordinated effort between primary care physicians and oncologists. Patients' medical care teams can be leveraged to help educate them about the importance of adherence to antiresorptive therapy when cancer has metastasized to bone. Because primary care physicians generally have more contact with their patients than oncologists, they are in a unique position to understand patient perceptions and habits that may lead to noncompliance and to help educate patients about the benefits and risks of various antiresorptive therapies in the advanced cancer setting. Therefore, primary care physicians need to be aware of various mechanistic and clinical considerations regarding antiresorptive treatment options.

Keywords: antiresorptive therapy, bisphosphonates, bone metastases, cancer, denosumab, zoledronic acid

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives

Díaz-López A, Moreno-Bueno G, Cano A

Cancer Management and Research 2014, 6:205-216

Published Date: 25 April 2014

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419

Raufi A, Ebrahim AS, Al-Katib A

Cancer Management and Research 2013, 5:225-233

Published Date: 27 August 2013

Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival

Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hoober JK, Eschbacher J, Liu R, Shi FD, Abdelwahab MG, Scheck AC, Preul MC

Cancer Management and Research 2012, 4:325-334

Published Date: 17 September 2012

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

Tuca A, Guell E, Martinez-Losada E, Codorniu N

Cancer Management and Research 2012, 4:159-169

Published Date: 13 June 2012

Use of neutral plasma coagulation in groin node dissection for vulvar malignancy: a novel technique

Madhuri TK, Tailor A, Butler-Manuel S

Cancer Management and Research 2011, 3:253-255

Published Date: 6 July 2011

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Gina M Mantia-Smaldone, Robert P Edwards, Anda M Vlad

Cancer Management and Research 2011, 3:25-38

Published Date: 30 December 2010

The disparity of health facilities in an urban area discourages proposed treatment application in inoperable lung cancer patients

Georgios Hillas, Petros Bakakos, Miltiadis Trichas, et al

Cancer Management and Research 2010, 2:287-291

Published Date: 15 November 2010